Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-040522
Filing Date
2019-11-06
Accepted
2019-11-05 18:07:52
Documents
99
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 FY2020 Q1 10-Q mygn-10q_20190930.htm   iXBRL 10-Q 2582225
2 EX-31.1 mygn-ex311_7.htm EX-31.1 15856
3 EX-31.2 mygn-ex312_10.htm EX-31.2 16326
4 EX-32.1 mygn-ex321_9.htm EX-32.1 6533
  Complete submission text file 0001564590-19-040522.txt   11542299

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA mygn-20190930.xsd EX-101.SCH 66600
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE mygn-20190930_cal.xml EX-101.CAL 87178
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mygn-20190930_def.xml EX-101.DEF 218737
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE mygn-20190930_lab.xml EX-101.LAB 521922
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mygn-20190930_pre.xml EX-101.PRE 414641
73 EXTRACTED XBRL INSTANCE DOCUMENT mygn-10q_20190930_htm.xml XML 2800086
Mailing Address 320 WAKARA WAY SALT LAKE CITY UT 84108
Business Address 320 WAKARA WAY SALT LAKE CITY UT 84108 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-26642 | Film No.: 191194545
SIC: 2835 In Vitro & In Vivo Diagnostic Substances